Top

Published in:

01-02-2021 | Azathioprine | Original article

Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience

Authors: Hepsen Mine Serin, Sanem Yilmaz, Erdem Simsek, Seda Kanmaz, Cenk Eraslan, Gul Aktan, Hasan Tekgul, Sarenur Gokben

Published in: Acta Neurologica Belgica | Issue 1/2021

Abstract

Anti-myelin oligodendrocyte glycoprotein antibodies have been associated with a wide range of clinical presentations including monophasic and relapsing disease courses. Lack of a definitive marker for predicting further relapses and the final diagnoses complicates the clinical follow-up and treatment decisions for patients with the first episode. This study retrospectively analyzed the clinical spectrum, treatment protocols and outcome of nine children with MOG antibody-associated demyelinating disease. Diagnoses at first presentation were acute disseminated encephalomyelitis (ADEM) in six cases (67%), optic neuritis in two cases (22%), and clinically isolated syndrome in one case (11%). The disease remained monophasic in five (56%) cases. All cases with a monophasic disease course were negative for anti-MOG antibody titers in the third month. The initial diagnosis of all relapsing cases was ADEM. Three of the four cases with a relapsing disease course were available for anti-MOG antibody testing at the third month and all were positive, however, antibody titers at the sixth month were inconsistent. Cases with a relapsing disease course had no further attacks after monthly intravenous immunoglobulin treatment. Relapsing disease course is not rare in childhood MOG-antibody associated demyelinating disease. Monthly IVIG treatment may be a good alternative for the long-term treatment of relapsing cases with a low side effect profile. Anti-MOG antibody serostatus at remission periods should be interpreted cautiously. Further studies are needed to better understand and predict the clinical course of pediatric patients with MOG-antibody associated diseases.

Ketelslegers IA, Van Pelt DE, Bryde S et al (2015) Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. MultScler 21:1513–1520

Fujihara K, Sato DK, Nakashima I et al (2018) Myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease: an overview. Clin Exp Neuroimmunol 9:48–55. https://doi.org/10.1111/cen3.12434CrossRef

O’Connor KC, McLaughlin KA, De Jager PL et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211–217CrossRef

Ramanathan S, Dale RC, Brilot F (2016) Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15:307–324CrossRef

Tegetmeyer H, Merkenschlager A (2017) Anti-myelin oligodendrocyte glycoprotein antibodies in paediatric patients with optic neuritis (in German). KlinMonblAugenheilkd 234:1243–1249

Hacohen Y, Absoud M, Deiva K et al (2015) Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. NeurolNeuroimmunolNeuroinflamm 2:e81

Hennes E-M, Baumann M, Schanda K et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89:900–908CrossRef

Konuskan B, Yildirim M, Gocmen R et al (2018) Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. MultSclerRelatDisord 26:1–7

Hacohen Y, Wong YY, Lechner C et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMANeurol 75:478–487

10.

Tanaka S, Hashimoto B, Izaki S et al (2020) Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: blood-brain barrier breakdown and peripheral plasmablasts. MultSclerRelatDisord 41:102005. https://doi.org/10.1016/j.msard.2020.102005CrossRef

11.

Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189CrossRef

12.

Krupp LB, Tardieu M, Amato MP et al (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. MultScler 19:1261–1267

13.

Mao L, Yang L, Kessi M et al (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody diseases in children in central south china: clinical features, treatments, influencing factors, and outcomes. Front Neurol 10:868. https://doi.org/10.3389/fneur.2019.00868CrossRefPubMedPubMedCentral

14.

Ramanathan S, Mohammad S, Tantsis E et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J NeurolNeurosurg Psychiatry 89:127–137CrossRef

15.

Baumann M, Sahin K, Lechner C et al (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J NeurolNeurosurg Psychiatry 86:265–272CrossRef

16.

Jarius S, Kleiter I, Ruprecht K et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement—frequency, presentation and outcome. J Neuroinflamm 13:281CrossRef

17.

Fernandez-Carbonell C, Vargas-Lowy D, Musallam A et al (2016) Clinical and MRI phenotype of children with MOG antibodies. MultScler 22:174–184

18.

Baumann M, Grams A, Djurdjevic T et al (2018) MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol 265:845–855CrossRef

19.

dos Passos GR, Oliveira LM, da Costa BK et al (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:217CrossRef

20.

Marignier R, Bernard-Valnet R, Giraudon P et al (2013) Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 80:2194–2200CrossRef

21.

Yan Y, Li Y, Fu Y et al (2016) Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci 59:1270–1281CrossRef

22.

Duignan S, Wright S, Rossor T et al (2018) Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 60:958–962CrossRef

23.

Dale RC, Tantsis EM, Merheb V et al (2014) Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. NeurolNeuroimmunolNeuroinflamm 1:e12

24.

Hyun J, Woodhall MR, Kim S et al (2017) Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J NeurolNeurosurg Psychiatry 88:811–817CrossRef

25.

Oliveira LM, Apóstolos-Pereira SL, Pitombeira MS et al (2018) Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. MultScler. https://doi.org/10.1177/1352458518811597CrossRef

26.

Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflamm 13:279CrossRef

27.

Rostásy K, Mader S, Hennes EM et al (2013) Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. MultScler 19(8):1052–1059. https://doi.org/10.1177/1352458512470310CrossRef

28.

Cobo-Calvo A, Ruiz A, Maillart E et al (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90:e1858–e1869. https://doi.org/10.1212/WNL.0000000000005560CrossRefPubMed

29.

López-Chiriboga AS, Majed M, Fryer J, Dubey D et al (2018) Association of MOG-IgGserostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMANeurol 75:1355

30.

Waters P, Fadda G, Woodhall M et al (2019) Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMANeurol. https://doi.org/10.1001/jamaneurol.2019.2940CrossRef

Title: Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience
Authors: Hepsen Mine Serin
Sanem Yilmaz
Erdem Simsek
Seda Kanmaz
Cenk Eraslan
Gul Aktan
Hasan Tekgul
Sarenur Gokben
Publication date: 01-02-2021
Publisher: Springer International Publishing
Keywords: Azathioprine
Optic Neuritis
Demyelinating Disease
Azathioprine
Published in: Acta Neurologica Belgica / Issue 1/2021
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-020-01499-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Adult-onset congenital central hypoventilation syndrome due to PHOX2B mutation

Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990–2016

Association between serum apolipoprotein E and cognitive functions in Egyptian patients with temporal lobe epilepsy

The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study

MNA-SF is not sufficient without questioning protein and fruit–vegetable consumption to detect malnutrition risk in Parkinson’s Disease

The effect of EMG biofeedback on lower extremity functions in hemiplegic patients